<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418249</url>
  </required_header>
  <id_info>
    <org_study_id>#69 REV 00</org_study_id>
    <nct_id>NCT00418249</nct_id>
  </id_info>
  <brief_title>Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women</brief_title>
  <official_title>Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and efficacy of topical AS101 as
      treatment for Female Androgenetic Alopecia (FAGA) in menopause women.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hair density</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hair diameter, anagen/telogen ratio and hair growth rate,Global photographic assessment according to Female-Ludwig scale,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-administered satisfaction questionnaire</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Alopecia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS101</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women in menopause, over 50 years of age.

          -  Clinically diagnosed for AGA, according to Ludwig scale I-II.

        Exclusion Criteria:

          -  Women treated with chronic medications.

          -  Use of Minoxidil within 3 months prior to entering study.

          -  Women who have underwent hair transplantation.

          -  Use of drugs with androgenic or anti-androgenic effects.

          -  Any other type of hair loss.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danny Ben-Amitai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danny Ben Amitai, MD</last_name>
    <phone>972-3-9253770</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raziel Lurie, MD</last_name>
    <email>rlurie@bezeqint.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danny Ben Amitai</last_name>
      <phone>972-3-9253770</phone>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>January 3, 2007</last_update_submitted>
  <last_update_submitted_qc>January 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2007</last_update_posted>
  <keyword>Androgenetic Alopecia</keyword>
  <keyword>Telogen effluvium</keyword>
  <keyword>Chronic telogen effluvium</keyword>
  <keyword>Menopause</keyword>
  <keyword>Female Androgenetic Alopecia (FAGA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ammonium trichloro(dioxoethylene-O,O'-)tellurate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

